Answers are grounded in this paper and cite their sources.
Dextran conjugation has aided the design of new tailor-made polymers with different molecular weights, shapes, structures and with the functional groups needed for coupling at the desired positions in the chain. Dextran prodrugs are very useful systems for achieving controlled drug release and drug targeting. In particular, various dextran-antitumor drug conjugates enhance the effectiveness and improve the cytotoxic effects of chemotherapeutic agents. Future studies should concentrate on barriers for their clinical use and safety as a drug carrier.
No takes yet. Share an insight, caveat, or question.
Jaleh Varshosaz (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: